Cargando…
Targeting cancers in the gastrointestinal tract: role of capecitabine
Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886333/ https://www.ncbi.nlm.nih.gov/pubmed/20616892 |
_version_ | 1782182473043542016 |
---|---|
author | Saif, Muhammad Wasif |
author_facet | Saif, Muhammad Wasif |
author_sort | Saif, Muhammad Wasif |
collection | PubMed |
description | Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers. |
format | Text |
id | pubmed-2886333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28863332010-07-08 Targeting cancers in the gastrointestinal tract: role of capecitabine Saif, Muhammad Wasif Onco Targets Ther Review Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers. Dove Medical Press 2009-02-18 /pmc/articles/PMC2886333/ /pubmed/20616892 Text en © 2009 Saif, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Saif, Muhammad Wasif Targeting cancers in the gastrointestinal tract: role of capecitabine |
title | Targeting cancers in the gastrointestinal tract: role of capecitabine |
title_full | Targeting cancers in the gastrointestinal tract: role of capecitabine |
title_fullStr | Targeting cancers in the gastrointestinal tract: role of capecitabine |
title_full_unstemmed | Targeting cancers in the gastrointestinal tract: role of capecitabine |
title_short | Targeting cancers in the gastrointestinal tract: role of capecitabine |
title_sort | targeting cancers in the gastrointestinal tract: role of capecitabine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886333/ https://www.ncbi.nlm.nih.gov/pubmed/20616892 |
work_keys_str_mv | AT saifmuhammadwasif targetingcancersinthegastrointestinaltractroleofcapecitabine |